Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Kamp, O; Metra, M; De Keulenaer, GW; Pieske, B; Conraads, V; Zamorano, J; Huysse, L; Vardas, PE; Bohm, M; Cas, LD.
Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study.
Clin Res Cardiol. 2010; 99(2):75-82 Doi: 10.1007/s00392-009-0098-x
Web of Science PubMed FullText FullText_MUG Google Scholar

Co-authors Med Uni Graz: Pieske Burkert Mathias
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: The SENIORS trial demonstrated that nebivolol has beneficial effects in patients with heart failure. However, the role of beta-blocker therapy in patients with heart failure and preserved left ventricular ejection fraction (HFPEF) is still unsettled. OBJECTIVE: To assess the long-term effects of administration of nebivolol, compared to placebo, on the clinical symptoms, exercise capacity and parameters of left ventricular (LV) function in patients with HFPEF. METHODS: The Effect of Long-term Administration of Nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with Diastolic Dysfunction (ELANDD) study is a prospective multicenter European trial in 120 patients with HFPEF randomised to nebivolol or placebo. HFPEF is defined as symptoms or signs of heart failure, a LV ejection fraction >45% and evidence of diastolic LV dysfunction by Doppler echocardiography. Procedures include a baseline clinical examination, 6-min walk test (6MWT), electrocardiography, Doppler echocardiography and Minnesota QoL questionnaire. Nebivolol or placebo is started at 2.5 mg/day and gradually uptitrated to 10 mg/day. After initiation of the study, patients are assessed at 1, 2, 5 and 6 weeks (titration phase) and at weeks 12 and 26. The primary endpoint is the change from baseline in the 6MWT distance with nebivolol versus placebo. Sample size calculations are based on an anticipated 15% difference (70 m) in the 6MWT distance between nebivolol and placebo-treated patients. This study will allow the collection of data regarding the possible clinical benefits and the effects on LV function of nebivolol administration in patients with HFPEF.
Find related publications in this database (using NLM MeSH Indexing): Aged -; Aged, 80 and over -; Antihypertensive Agents - administration and dosage; Benzopyrans - administration and dosage; Comorbidity -; Drug Toxicity - epidemiology; Ethanolamines - administration and dosage; Ethanolamines - epidemiology; Female -; Heart Failure - diagnosis Heart Failure - drug therapy Heart Failure - epidemiology; Humans -; Incidence -; Longitudinal Studies -; Male -; Middle Aged -; Treatment Outcome -; Ventricular Dysfunction, Left - diagnosis Ventricular Dysfunction, Left - drug therapy Ventricular Dysfunction, Left - epidemiology
Find related publications in this database (Keywords): HFPEF (heart failure preserved ejection fraction); 6 MWT; Nebivolol; Quality of life; ELANDD